Pieris Pharmaceuticals Management
Management criteria checks 2/4
Pieris Pharmaceuticals' CEO is Steve Yoder, appointed in Dec 2014, has a tenure of 9.33 years. total yearly compensation is $2.06M, comprised of 27.4% salary and 72.6% bonuses, including company stock and options. directly owns 0.006% of the company’s shares, worth $1.03K. The average tenure of the management team and the board of directors is 4.5 years and 6.5 years respectively.
Key information
Steve Yoder
Chief executive officer
US$2.1m
Total compensation
| CEO salary percentage | 27.4% |
| CEO tenure | 9.3yrs |
| CEO ownership | 0.006% |
| Management average tenure | 4.5yrs |
| Board average tenure | 6.5yrs |
Recent management updates
Recent updates
We Think Pieris Pharmaceuticals (NASDAQ:PIRS) Needs To Drive Business Growth Carefully
Mar 19
Pieris Pharmaceuticals, Inc. (NASDAQ:PIRS) Not Doing Enough For Some Investors As Its Shares Slump 27%
Dec 18We Think Pieris Pharmaceuticals (NASDAQ:PIRS) Needs To Drive Business Growth Carefully
Aug 18Analysts Just Shaved Their Pieris Pharmaceuticals, Inc. (NASDAQ:PIRS) Forecasts Dramatically
May 15Why Investors Shouldn't Be Surprised By Pieris Pharmaceuticals, Inc.'s (NASDAQ:PIRS) 41% Share Price Plunge
Apr 17Can Pieris Pharmaceuticals (NASDAQ:PIRS) Afford To Invest In Growth?
Dec 31Bearish: This Analyst Is Revising Their Pieris Pharmaceuticals, Inc. (NASDAQ:PIRS) Revenue and EPS Prognostications
Aug 10Pieris Pharmaceuticals GAAP EPS of -$0.14 misses by $0.03, revenue of $3.7M misses by $6.77M
Aug 04Pieris: Early Stage Developer Of Novel Asset Class
Jan 09We're Not Very Worried About Pieris Pharmaceuticals' (NASDAQ:PIRS) Cash Burn Rate
Dec 15Progress At Pieris Pharmaceuticals
Oct 27Analysts Just Made A Noticeable Upgrade To Their Pieris Pharmaceuticals, Inc. (NASDAQ:PIRS) Forecasts
Aug 05We Think Pieris Pharmaceuticals, Inc.'s (NASDAQ:PIRS) CEO Compensation Package Needs To Be Put Under A Microscope
Jun 19Need To Know: Analysts Just Made A Substantial Cut To Their Pieris Pharmaceuticals, Inc. (NASDAQ:PIRS) Estimates
May 22Will Pieris Pharmaceuticals (NASDAQ:PIRS) Spend Its Cash Wisely?
May 19Analysts Are Betting On Pieris Pharmaceuticals, Inc. (NASDAQ:PIRS) With A Big Upgrade This Week
Apr 01Here's What Pieris Pharmaceuticals, Inc.'s (NASDAQ:PIRS) Shareholder Ownership Structure Looks Like
Mar 08We're Keeping An Eye On Pieris Pharmaceuticals' (NASDAQ:PIRS) Cash Burn Rate
Feb 01How Much Did Pieris Pharmaceuticals'(NASDAQ:PIRS) Shareholders Earn From Share Price Movements Over The Last Three Years?
Dec 28
How Does Pieris Pharmaceuticals' (NASDAQ:PIRS) CEO Salary Compare to Peers?
Dec 02CEO Compensation Analysis
| Date | Total Compensation | Salary | Company Earnings |
|---|---|---|---|
| Dec 31 2023 | n/a | n/a | -US$25m |
| Sep 30 2023 | n/a | n/a | -US$28m |
| Jun 30 2023 | n/a | n/a | -US$27m |
| Mar 31 2023 | n/a | n/a | -US$41m |
| Dec 31 2022 | US$2m | US$565k | -US$33m |
| Sep 30 2022 | n/a | n/a | -US$35m |
| Jun 30 2022 | n/a | n/a | -US$42m |
| Mar 31 2022 | n/a | n/a | -US$47m |
| Dec 31 2021 | US$2m | US$548k | -US$46m |
| Sep 30 2021 | n/a | n/a | -US$51m |
| Jun 30 2021 | n/a | n/a | -US$48m |
| Mar 31 2021 | n/a | n/a | -US$38m |
| Dec 31 2020 | US$2m | US$535k | -US$37m |
| Sep 30 2020 | n/a | n/a | -US$26m |
| Jun 30 2020 | n/a | n/a | -US$15m |
| Mar 31 2020 | n/a | n/a | -US$22m |
| Dec 31 2019 | US$2m | US$515k | -US$28m |
| Sep 30 2019 | n/a | n/a | -US$36m |
| Jun 30 2019 | n/a | n/a | -US$40m |
| Mar 31 2019 | n/a | n/a | -US$28m |
| Dec 31 2018 | US$3m | US$500k | -US$27m |
| Sep 30 2018 | n/a | n/a | -US$8m |
| Jun 30 2018 | n/a | n/a | -US$8m |
| Mar 31 2018 | n/a | n/a | -US$18m |
| Dec 31 2017 | US$1m | US$450k | -US$18m |
Compensation vs Market: Steve's total compensation ($USD2.06M) is above average for companies of similar size in the US market ($USD663.70K).
Compensation vs Earnings: Steve's compensation has increased whilst the company is unprofitable.
CEO
Steve Yoder (47 yo)
9.3yrs
Tenure
US$2,062,843
Compensation
Mr. Stephen S. Yoder, also known as Steve, J.D., has been the Chief Executive Officer and President at Pieris Pharmaceuticals, Inc. since December 17, 2014. Mr. Yoder joined Pieris Pharmaceuticals GmbH as...
Leadership Team
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| CEO, President & Director | 9.3yrs | US$2.06m | 0.0061% $ 1.0k | |
| Senior VP | 4.6yrs | US$943.56k | 0.019% $ 3.3k | |
| Executive Director of Investor Relations | no data | no data | no data | |
| Senior VP & Chief Development Officer | no data | no data | no data | |
| Chief Supply Chain Officer | 4.5yrs | no data | no data | |
| VP and Head of Alliance Management & Early Project Leadership | 1.3yrs | no data | no data |
4.5yrs
Average Tenure
47yo
Average Age
Experienced Management: PIRS's management team is considered experienced (4.5 years average tenure).
Board Members
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| CEO, President & Director | 9.3yrs | US$2.06m | 0.0061% $ 1.0k | |
| Independent Chairman | 6.9yrs | US$136.73k | 0.020% $ 3.4k | |
| Independent Director | 9.3yrs | US$93.98k | 0% $ 0 | |
| Independent Director | 7.6yrs | US$109.98k | 0.020% $ 3.4k | |
| Independent Director | 5.6yrs | US$102.48k | 0% $ 0 | |
| Independent Director | 5.5yrs | US$94.98k | 0% $ 0 | |
| Independent Director | 6yrs | US$93.98k | 0% $ 0 | |
| Independent Director | 4.8yrs | US$93.98k | 0% $ 0 | |
| Member of Clinical & Scientific Advisory Board | no data | no data | no data | |
| Member of Clinical & Scientific Advisory Board | no data | no data | no data | |
| Member of Clinical & Scientific Advisory Board | no data | no data | no data | |
| Member of Clinical & Scientific Advisory Board | no data | no data | no data |
6.5yrs
Average Tenure
60yo
Average Age
Experienced Board: PIRS's board of directors are considered experienced (6.5 years average tenure).